Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. (“Grifols”) hereby informs about the following

RELEVANT EVENT

Grifols presents AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/III) at the “Clinical Trials on Alzheimer’s Disease” (CTAD) congress today in Barcelona.

AMBAR, an innovative treatment approach for Alzheimer’s disease using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate Alzheimer’s disease patients. The analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer’s disease.

The results in the prespecified cohort of Moderate Alzheimer’s patients demonstrated a statistically significant reduction of 61% in disease progression in both primary efficacy endpoints measuring cognition and activities of daily living during a 14 month period. While a consistent delay in the progression of disease was observed in the treatment arm for the pre-specified mild cohort (the placebo arm presented a similar pattern) and the difference did not reach statistical significance.

The combination of Plasmapheresis (a well-known and safe procedure used in plasma exchange) with Albutein® 20% (albumin, a safe, well tolerated plasma protein with multiple properties) has demonstrated a significant reduction in the progression of the disease in the moderate Alzheimer’s disease patients participating in the study and may offer a new treatment pathway for the illness.

For more information on AMBAR please visit Grifols’ webpage www.grifols.com

In Barcelona, on 27 October 2018

Nuria Martín Barnés
Secretary to the Board of Directors